<tbody id="jftbj"></tbody>

              A POWERFUL RESEARCH AND
              DEVELOPMENT ENGINE

              Our unique ability to repeatedly and consistently translate science into medicine has led to a robust pipeline of clinical-stage medicines, all of which were discovered in our laboratories. Our investigational treatments target allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

              • Phase 1 trials

                Phase 1 Trials

                CEMIPLIMAB*

                PD-1 Antibody
                Cancer

                REGN3767

                LAG-3 Antibody
                Cancer

                REGN1979

                CD20xCD3 Antibody
                Cancer

                REGN4018*

                MUC16xCD3 Antibody
                Cancer

                REGN4659

                CTLA4 Antibody
                Cancer

                REGN5458*

                BCMAxCD3 Antibody
                Cancer

                REGN3048-3051

                Middle East Respiratory Coronavirus Antibody
                MERS-CoV infection

                REGN4461

                LEPR Antibody
                Lipodystrophy and obesity

                REGN5713-5714-5715

                Betv1 Antibody
                Birch Allergy
              • Phase 2 trials

                Phase 2 Trials

                CEMIPLIMAB*

                PD-1 Antibody
                Basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (CSCC)
                REGN1979
                CD20xCD3 Antibody
                Relapsed / refractory follicular lymphoma

                DUPILUMAB*

                IL-4R Antibody
                Grass allergy, peanut allergy

                SARILUMAB*

                IL-6R Antibody
                Polyarticular-course juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis

                REGN1908-1909

                Fel d 1 Antibody
                Cat allergy

                REGN3500*

                IL-33 Antibody
                Asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis

                REGN5069

                GFRα3 Antibody
                Osteoarthritis knee pain

                GARETOSMAB

                Activin A Antibody
                Fibrodysplasia Ossificans Progressiva (FOP)

                EVINACUMAB

                ANGPTL-3 Antibody
                Refractory hypercholesterolemia (both HeFH and non-FH), severe hypertriglyceridemia

                POZELIMAB

                C5 Antibody
                Paroxysmal nocturnal hemoglobinuria
              • Phase 3 trials

                Phase 3 Trials

                AFLIBERCEPT
                VEGF-Trap
                Non-proliferative diabetic retinopathy (NPDR) without DME

                ALIROCUMAB*

                PCSK9 Antibody
                Homozygous familial hypercholesterolemia (HoFH) in adults and pediatrics, heterozygous familial hypercholesterolemia in pediatrics

                CEMIPLIMAB*

                PD-1 Antibody
                Non-small cell lung cancer, cervical cancer

                REGN-EB3

                Ebola Virus Antibody
                Ebola virus infection

                DUPILUMAB*

                IL-4R Antibody
                Atopic dermatitis in pediatrics, asthma in pediatric, eosinophilic esophagitis, COPD

                SARILUMAB*

                IL-6R Antibody
                Polymyalgia rheumatica, giant cell arteritis

                EVINACUMAB

                ANGPTL-3 Antibody
                Homozygous familial hypercholesterolemia (HoFH)

                FASINUMAB?

                NGF Antibody
                Chronic pain from osteoarthritis of the knee or hip

              Trials Footnotes

              * in collaboration with Sanofi

              ? in collaboration with Teva and Mitsubishi Tanabe

              This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.

              伊人久久大香线蕉综合